血液透析患者应用左卡尼汀的疗效观察  

Therapeutic effect of L-carnitine in patients receiving hemodialysis

作　　者：王开利[1] 邢汉前[1] 刘俊微[1] 赵鸿[1] 姚宏宇[1] 张雪华[1] 赵军[1] 

机构地区：[1]解放军第302医院血液净化科,北京100039

出　　处：《军医进修学院学报》2012年第12期1276-1277,共2页Academic Journal of Pla Postgraduate Medical School

摘　　要：目的观察左卡尼汀对维持性血液透析患者的疗效。方法回顾分析我院2010年12月-2011年12月应用左卡尼汀的14例血液透析患者的临床资料。结果 14例患者在应用左卡尼汀12个月后,血红蛋白、白蛋白无明显变化,重组人促红素用量较前减少(P<0.05);对脂肪酸代谢的影响:apo-A1在治疗后较前下降(P<0.05),余指标在应用前后变化无统计学意义。结论左卡尼汀可减少血透患者促红细胞生成素的需求,但对白蛋白及脂肪酸代谢并无改善作用。Objective To observe the therapeutic effect of L-carnitine in patients receiving hemodialysis. Methods Clinical data about 14 patients who underwent L-carnitine hemodialysis in our hospital from December 2010 to December 2011 were retrospectively analyzed. Results No significant change of hemoglobin and albumin occurred in the 14 patients 12 months after L-carnitine hemodialysis（P〉0.05）. The dose of recombinant human erythropoietin（EPO） was reduced（P〈0.05）. The Apo-A1 was significantly lower after treatment than before treatment（P〈0.05） while no significant difference was found in the other indexes before and after treatment（P〉0.05）. Conclusion L-carnitine can reduce the need of EPO in patients receiving hemodialysis and has no effect on albumin and lipid metabolism.

关 键 词：血液透析 左卡尼汀 脂代谢 

分 类 号：R969.4[医药卫生—药理学]